The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...

The U.S. FDA on Tuesday granted traditional approval for a first-line combination regimen involving Braftovi, an oral cancer drug developed by Pfizer (PFE) in partnership with companies such as ...

Roche ( RHHBF) ( RHHBY) shares fell after the Swiss drugmaker’s investigational breast cancer pill failed to meet the primary goal of a late-stage breast cancer trial.

The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a candidate to become a blockbuster treatment.